Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?

Jeremy W. Jacobs, Laura D. Stephens, David M. Chooljian, Deva Sharma, Brian D. Adkins, Garrett S. Booth

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Journal	American Journal of Hematology
DOIs	https://doi.org/10.1002/ajh.27275
State	Accepted/In press - 2024

ASJC Scopus subject areas

@article{c460718c564b4c5e8a1e30639c5d5d77,

title = "Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?",

author = "Jacobs, {Jeremy W.} and Stephens, {Laura D.} and Chooljian, {David M.} and Deva Sharma and Adkins, {Brian D.} and Booth, {Garrett S.}",

year = "2024",

doi = "10.1002/ajh.27275",

language = "English (US)",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Crizanlizumab and sickle cell disease

T2 - When should medications have their approval status revoked?

AU - Jacobs, Jeremy W.

AU - Stephens, Laura D.

AU - Chooljian, David M.

AU - Sharma, Deva

AU - Adkins, Brian D.

AU - Booth, Garrett S.

PY - 2024

Y1 - 2024

UR - http://www.scopus.com/inward/record.url?scp=85186586096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85186586096&partnerID=8YFLogxK

U2 - 10.1002/ajh.27275

DO - 10.1002/ajh.27275

M3 - Comment/debate

C2 - 38409818

AN - SCOPUS:85186586096

SN - 0361-8609

JO - American Journal of Hematology

JF - American Journal of Hematology

ER -